Get the latest Science News and Discoveries

Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC


None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of NSCLC

NSCLC

Photo of Lorlatinib

Lorlatinib

Related news:

News photo

Radiation Oncology trials using PET with FDG uptake among NSCLC patients

News photo

Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC

News photo

Sotorasib provides durable clinical benefit for patients with NSCLC and KRAS mutations